AMPH at a glance
Amphastar Pharmaceuticals, Inc. (AMPH, SEC CIK 1297184) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as September 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $719.9 million (down 1.7% from FY2024) and net income of $98.1 million. Diluted EPS was $2.03.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Amphastar Pharmaceuticals, Inc. (AMPH) shares worth $319.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by PETERS WILLIAM J on September 21, 2026 of 4,139 shares at $25.00 per share.
- In the last 90 days, AMPH insiders reported 0 open-market purchases ($0) and 5 open-market sales ($764K) on Form 4, a net sale of $764K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $719.9M
- −1.7% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$764K
- 13F holders
- 31 funds
- $319.8M · +1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly triggered FDA warning letter: IMS’s South El Monte facility received a July 2, 2026 letter citing finished-pharmaceutical cGMP violations
- Regulatory remediation risk: IMS voluntarily suspended one product while prioritizing products at shortage risk
- Operational risk: FDA may pursue additional action if IMS deficiencies remain unresolved
- Financial market risk: Lenders’ collateral includes 5,700,000 pledged shares, potentially pressuring Amphastar’s stock price
- Concentration risk: UBS can unilaterally call $15.0 million in credit lines for any reason
AI summary of the AMPH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Amphastar reported financial results for the three months ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the quarter’s detailed financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $183.9M, up 5%; gross margin improved to 50.8% from 49.6%, supported by higher-margin launches
- GAAP net income $30.3M, down from $31.0M; diluted EPS increased to $0.67 from $0.64 on fewer shares
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 10 to 11 directors with Anthony Pierce appointed as Class III director through 2028 annual meeting
- Pierce deemed Nasdaq-independent, with no related-party transactions or selection arrangements disclosed
Item 8.01: Other Events
- IMS received an FDA warning letter on July 2, 2026, after a December 2025 inspection of its South El Monte, California facility
- CGMP deficiencies involve investigations, environmental monitoring, handling procedures, and manufacturing equipment
AI summaries of AMPH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AMPH
Don't miss the next AMPH filing
- Alerts as it files. A push when AMPH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AMPH, by share count.
- Ask anything. An AI agent that reads every AMPH filing and answers with sources.
AMPH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| PETERS WILLIAM J | Sell | Sep 21, 2026 | 4,139 | $25.00 |
| Zhou Rong | Sell | Sep 16, 2026 | 10,000 | $23.94 |
| Zhou Rong | M | Sep 16, 2026 | 10,000 | - |
| Zhou Rong | M | Sep 16, 2026 | 10,000 | $13.35 |
| Zhou Rong | Sell | Sep 2, 2026 | 3,187 | $23.63 |
| PRINS RICHARD K | Sell | Aug 11, 2026 | 7,973 | $20.30 |
| PETERS WILLIAM J | Sell | Aug 7, 2026 | 8,180 | $22.48 |
| PETERS WILLIAM J | M | Aug 7, 2026 | 5,053 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $732.0M | $719.9M |
| Gross Profit | - | $373.9M | $356.1M |
| Operating Income | - | $205.4M | $140.4M |
| Net Income | - | $159.5M | $98.1M |
| Gross Margin | - | 51.1% | 49.5% |
| Op. Margin | - | 28.1% | 19.5% |
| Net Margin | - | 21.8% | 13.6% |
| Balance Sheet | |||
| Total Assets | $1.5B | $1.6B | $1.6B |
| Equity | $639.4M | $732.3M | $788.8M |
| ROE | - | 21.8% | 12.4% |
| Per Share | |||
| EPS | - | $3.06 | $2.03 |
| Cash Flow | |||
| Operating CF | - | $213.4M | $156.1M |
| CapEx | - | $41.0M | $34.9M |
Source: XBRL data in Amphastar Pharmaceuticals, Inc. (AMPH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AMPH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $319.8M |
| Q1 2026 | 30 | $316.3M |
| Q4 2025 | 28 | $438.5M |
| Q3 2025 | 29 | $451.5M |
| Q2 2025 | 28 | $388.7M |
| Q1 2025 | 26 | $287.9M |
| Q4 2024 | 23 | $314.6M |
| Q3 2024 | 21 | $259.6M |
- Dimensional Fund Advisors+277.2K (+14%)
- D.E. Shaw & Co+221.5K (+33%)
- Goldman Sachs Group+176.0K (+53%)
- AQR Capital Management+129.9K (+165%)
- Two Sigma Investments+110.0K (+80%)
- Invesco Ltd−446.7K (-74%)
- Millennium Management−339.6K (-91%)
- BlackRock−196.4K (-4%)
- Franklin Resources−114.3K (-82%)
- Vanguard Capital Management LLC−61.7K (-4%)
- Allstate+11.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 216 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AMPH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Jul 14, 2026 | - | - | |
| 4 | Jul 13, 2026 | - | - | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 8-K | Jul 8, 2026 | - | Analysis | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 3, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 8-K | Mar 16, 2026 | - | Analysis | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AMPH SEC filings: frequently asked questions
Are AMPH insiders buying or selling?
In the last 90 days, Amphastar Pharmaceuticals, Inc. (AMPH) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $763,923 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AMPH stock?
As of June 30, 2026, the largest Amphastar Pharmaceuticals, Inc. (AMPH) holders among the 13F filers tracked by SignalX were BlackRock ($105.4 million), Dimensional Fund Advisors ($46.5 million), State Street Corp ($33.1 million), Vanguard Capital Management LLC ($29.9 million), D.E. Shaw & Co ($17.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AMPH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $719.9 million (down 1.7% from FY2024) and net income of $98.1 million. Diluted EPS was $2.03. The figures come from the XBRL data in the 10-K.
What did AMPH report in its latest 8-K?
Amphastar Pharmaceuticals, Inc. (AMPH) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Amphastar reported financial results for the three months ended June 30, 2026.
What are the latest AMPH SEC filings?
Amphastar Pharmaceuticals, Inc. (AMPH) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on September 23, 2026.
What is AMPH's SEC CIK number?
Amphastar Pharmaceuticals, Inc. (AMPH)'s SEC Central Index Key (CIK) is 1297184. EDGAR lists every AMPH filing under that number.
Ask anything about AMPH
The research agent reads AMPH's filings, financials, insider trades and 13F holders, then answers with sources.